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Increased Hazard of Myocardial Infarction With Insulin-Provision
Therapy in Actively Smoking Patients With Diabetes Mellitus and
Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) Trial
Asrar A. Khan, MD;* Matthew J. Chung, MD;* Eric Novak, MS; David L. Brown, MD
Background-—In the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial, randomization of diabetic
patients with stable ischemic heart disease to insulin provision (IP) therapy, as opposed to insulin sensitization (IS) therapy,
resulted in biochemical evidence of impaired ﬁbrinolysis but no increase in adverse clinical outcomes. We hypothesized that the
prothrombotic effect of IP therapy in combination with the hypercoagulable state induced by active smoking would result in an
increased risk of myocardial infarction (MI).
Methods and Results-—We analyzed BARI 2D patients who were active smokers randomized to IP or IS therapy. The primary end
point was fatal or nonfatal MI. PAI-1 (plasminogen activator inhibitor 1) activity was analyzed at 1, 3, and 5 years. Of 295 active
smokers, MI occurred in 15.4% randomized to IP and in 6.8% randomized to IS over the 5.3 years (P=0.023). IP therapy was
associated with a 3.2-fold increase in the hazard of MI compared with IS therapy (hazard ratio: 3.23; 95% conﬁdence interval, 1.43–
7.28; P=0.005). Baseline PAI-1 activity (19.0 versus 17.5 Au/mL, P=0.70) was similar in actively smoking patients randomized to
IP or IS therapy. However, IP therapy resulted in signiﬁcantly increased PAI-1 activity at 1 year (23.0 versus 16.0 Au/mL,
P=0.001), 3 years (24.0 versus 18.0 Au/mL, P=0.049), and 5 years (29.0 versus 15.0 Au/mL, P=0.004) compared with IS
therapy.
Conclusions-—Among diabetic patients with stable ischemic heart disease who were actively smoking, IP therapy was
independently associated with a signiﬁcantly increased hazard of MI. This ﬁnding may be explained by higher PAI-1 activity in active
smokers treated with IP therapy.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00006305. ( J Am Heart Assoc. 2017;6:
e005946. DOI: 10.1161/JAHA.117.005946.)
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P atients with type 2 diabetes mellitus and stable ischemicheart disease (SIHD) are at increased risk of myocardial
infarction (MI) compared with their nondiabetic counter-
parts.1–5 The increased risk is thought to be mediated by a
multifactorial diabetic vasculopathy resulting in a prothrom-
botic coronary vascular milieu.6 Potentially compounding this
prothrombotic tendency, treatment of diabetes mellitus with
insulin provision pharmacotherapy impairs ﬁbrinolysis. In the
BARI 2D (Bypass Angioplasty Revascularization Investigation 2
Diabetes) trial of patients with diabetes mellitus and SIHD,
PAI-1 (plasminogen activator inhibitor 1) antigen and activity
levels increased in those randomized to an insulin provision
(IP) strategy compared with those randomized to an insulin
sensitization (IS) strategy. Despite the signiﬁcant differences
in ﬁbrinolytic biomarker proﬁles, no difference was observed
in death or major cardiovascular events between the 2
treatment strategies.7,8 Active cigarette smoking also induces
a multifactorial hypercoagulable state through increased
synthesis of PAI-1, elevation in the blood ﬁbrinogen concen-
tration, increased platelet activity, and increased expression
of tissue factor and is associated with an increased risk of MI
in both diabetic and nondiabetic patients with SIHD.9 We
hypothesized that in diabetic patients with SIHD, the
prothrombotic effects of IP therapy in combination with the
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hypercoagulable state induced by active smoking would result




The BARI 2D data set was obtained on request from the
Biologic Specimen and Data Repository Information Coordi-
nating Center of the National Heart, Lung, and Blood Institute
under a data use agreement. The Washington University
Human Research Protection Ofﬁce granted this study an
exemption from institutional review board oversight.
Study Design
The rationale and design of the BARI 2D trial have been
described previously.10,11 Brieﬂy, the BARI 2D trial random-
ized 2368 patients with both type 2 diabetes mellitus and
SIHD to receive either prompt revascularization with percu-
taneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) in addition to intensive medical therapy or to
intensive medical therapy alone and to receive either IS or IP
therapy. Randomization was stratiﬁed according to the
method of revascularization, PCI or CABG, selected by the
treating physician to be the optimal treatment for each
patient.
Study Patients
Participants in the BARI 2D trial were recruited between
January 1, 2001, and March 31, 2005, at 49 clinical sites
in the United States, Brazil, Canada, Mexico, Austria, and
the Czech Republic. Participants had to be ≥25 years old
with a diagnosis of type 2 diabetes mellitus and coronary
artery disease (≥50% stenosis of a major epicardial
coronary artery associated with a positive stress test or
≥70% stenosis of a major epicardial coronary artery and
classic angina). All patients had to be eligible for either
elective PCI or CABG. The main exclusion criteria were the
need for immediate revascularization, left main coronary
disease, coronary revascularization within the 12 months
before randomization, class III or IV heart failure, hepatic
dysfunction, serum creatinine >2.0 mg/dL (177 lmol/L),
and glycosylated hemoglobin level (HbA1c) >13.0%. The
protocol was approved by each institution’s review board or
ethics committee. All participants provided written informed
consent.
Treatment and Follow-up
Patients were randomized to either an IS strategy for
treatment of hyperglycemia using primarily metformin and/
or a thiazolidinedione drug or an IP strategy using primarily a
sulfonylurea and/or a meglitinide drug and insulin itself.
Patients randomized to the prompt revascularization strategy
were to undergo PCI or CABG within 4 weeks of randomiza-
tion. Patients in the intensive medical therapy group were
permitted to receive revascularization only if they developed
worsening angina, severe ischemia, or an acute coronary
syndrome. Intensive medical therapy in both strategies
consisted of lifestyle management targeting smoking cessa-
tion, weight loss, and regular exercise as well as pharmaco-
logical therapy according to contemporary guidelines to
maintain HbA1c <7.0%, low-density lipoprotein cholesterol
<100 mg/dL (2.6 mmol/l), and blood pressure ≤130/
80 mm Hg. Patients were evaluated monthly for 6 months
and every 3 months thereafter for a mean follow-up of
5.3 years. Smoking status (active, former or never) was
ascertained for all patients at baseline; 6 months; and 1, 2, 3,
4, and 5 years.
Outcomes
The primary end point for the present analysis was fatal or
nonfatal MI. All myocardial ischemic events requiring hospi-
talization were adjudicated based on source documents
including emergency department records, admission history
and physical examination, ECGs and biomarkers, discharge
summaries, and records of revascularization procedures.2 The
BARI 2D criteria for MI required that an abnormal biomarker
proﬁle exceed at least twice the upper limits of normal for the
local laboratory. When cardiac troponin and creatine kinase-
MB were acquired simultaneously, cardiac troponin took
precedence in establishing the diagnosis of MI. MI was
conﬁrmed in the presence of abnormal cardiac biomarkers
and evidence of angina or angina-equivalent symptoms, ECG
or imaging evidence of new myocardial ischemia, or autopsy
Clinical Perspective
What Is New?
• Diabetic patients with stable ischemic heart disease who
smoke and are treated with insulin provision therapy as
opposed to insulin sensitization therapy may be at increased
risk of myocardial infarction.
What Are the Clinical Implications?
• Preferential treatment with insulin sensitization therapy
rather than insulin provision therapy should be considered
for the care of diabetic patients with stable ischemic heart
disease who smoke.
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evidence of new MI. All ECGs were interpreted at the core
laboratory with the use of the Minnesota code with an
adaptation of the NOVACODE for serial ECG compar-
isons.12,13 A Q-wave MI required the development of new
pathological Q waves13 or the new occurrence of a left
bundle-branch block in addition to abnormal biomarkers.
Non–Q-wave MI required the aforementioned MI criteria
without new pathological Q waves. Fatal MIs were deﬁned as
death occurring within 30 days after the event with a causal
relationship to the death.
Table 1. Baseline Characteristics of Active Smokers
Total IS IP P Value
No. of patients 295 152 143
Age, y, meanSD 577 578 577 0.76
Female, % 24 28 20 0.14
Nonwhite, % 35 40 30 0.09
Clinical characteristics, %
History of MI 59 58 60 0.81
History of CHF 6 4 9 0.01
Hypertension 77 75 79 0.40
Hypercholesterolemia 76 70 83 0.013
Cerebrovascular accident 12 10 13 0.37
Prior revascularization 22 17 27 0.049
ABI ≤0.9 34 35 33 0.80
Insulin use 28 28 28 0.90
Cardiovascular risk factors
BMI, meanSD 316 317 315 0.71
HDL-C, mg/dL, meanSD 3711 3710 3811 0.44
LDL-C, mg/dL, meanSD 9933 9931 9836 0.94
HbA1c, %, meanSD 7.81.7 8.11.8 7.51.6 0.006
Regular exercise, % 18 21 15 0.22
Treatment randomization
SIHD treatment, % 0.91
Medical therapy 48 48 49
Prompt revascularization 52 52 51
ABI indicates ankle brachial index; BMI, body mass index; CHF, congestive heart failure; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IP indicates insulin
provision; IS, insulin sensitization; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; SIHD, stable ischemic heart disease.
Table 2. Use of Recommended Medications Among Active Smokers Over Time by Diabetes Mellitus Treatment Strategy
Treatment
Baseline Year 1 Year 3 Year 5
IS IP P Value IS IP P Value IS IP P Value IS IP P Value
No. of patients 152 143 114 103 112 83 60 39
Aspirin, % 81 89 0.07 90 93 0.62 89 94 0.40 88 97 0.24
Statin, % 67 80 0.012 96 93 0.35 93 97 0.47 94 93 1.00
ACEI/ARB, % 70 79 0.08 83 90 0.23 90 88 0.80 98 93 0.55
Beta blocker, % 70 74 0.52 84 85 0.85 91 76 0.012 92 77 0.09
All 4 medication classes, % 36 48 0.044 66 68 0.77 72 66 0.49 76 77 1.00
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; IP, insulin provision; IS, insulin sensitization.
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Insulin, tissue plasminogen activator (tPA) antigen, and PAI-1
activity samples were drawn by peripheral venipuncture,
placed on ice within 15 minutes, centrifuged for separation of
plasma, frozen, and shipped in batches to the core laboratory.
Insulin, tPA antigen, and PAI-1 assays were performed by
ELISA. The tPA activity was not measured because it
complexes with excess PAI-1 in plasma resulting in activity
that is undetectable.7 PAI-1 activity was assayed with a
chromogenic substrate kinetic procedure.
Statistical Analyses
Because we were interested in the prothrombotic effects of
active smoking, we compared patients who were actively
smoking to those who were not smoking at the time of
assessment (never and former smokers). Continuous vari-
ables were compared using the Student t test for indepen-
dent groups, and categorical variables were compared with
the v2 or Fisher exact test, as appropriate. Non-normal data
were summarized by the median (ﬁrst, third quartiles) and






































































































































































































































































































































































































































Figure 1. A, Rates of freedom from fatal or nonfatal MI in active
smokers (smoking status as a time-dependent variable) with IS vs
IP therapy. B, Rates of freedom from fatal or nonfatal MI in
nonsmokers (smoking status as a time-dependent variable) with
IS vs IP therapy. IP indicates insulin provision; IS, insulin
sensitization; MI, myocardial infarction.
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was made for multiple comparisons. Kaplan–Meier curves
were created by insulin therapy strategy to examine the
rates of fatal and nonfatal MI by smoking status as deﬁned
at baseline and were compared using the log-rank test.
Risk-factor levels and medication use during follow-up were
compared based on concurrent smoking status. We evalu-
ated the independent effect of IP (compared with IS)
therapy on MI among smokers and nonsmokers by including
smoking status, therapy, and the interaction between
smoking status and therapy in a multivariable Cox regres-
sion model. In addition, variables with univariate P<0.10 in
baseline comparisons of smokers randomized to IS versus
IP were included in the model. These included race,
hypercholesterolemia, HbA1c level, prior revascularization,
aspirin use, statin use, angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker use, and biguanide
use. In addition, age, sex, and beta blocker use were forced
into the model given their relation to MI. The risk of MI for
IP therapy (versus IS) was summarized via the adjusted
hazard ratios (HRs) and 95% conﬁdence intervals from the
multivariable model for both smokers and nonsmokers. The
difference in HRs between smokers and nonsmokers was
evaluated by smoking status and therapy interaction term.
Smoking status was treated as an updated time-dependent
exposure variable. In the event that smoking status was
missing for a subject at any time point from study entry to
the last follow-up, the smoking status of the previous time
point was used. Statistical signiﬁcance was assessed using
2-sided P values, with P<0.05 considered statistically




Of 2360 patients with known smoking status, 295 were active
smokers at baseline. Among active smokers, the mean age was
57 years, 76%weremale, and 65%werewhite. At baseline, 33.1%
of patients had never smoked, 54.4% were former smokers, and
12.5% were current smokers. Among the 295 patients who
smokedat studyentry, themean (SD)daily number ofcigarettes
smoked was 1512. At 1, 3, and 5 years, 9.9%, 9.8%, and 9.9%,
respectively, were active smokers. Of those who smoked at
baseline, 53% had a change in smoking status at any of the follow-
up visits. Conversely, of the 2065 nonsmokers at baseline, 4%
smoked at some time during the study.
Of the 295 active smokers at baseline, 143 were
randomized to IP therapy and 152 were randomized to IS
therapy. Patients in the IP arm were more likely to have
hypercholesterolemia, more often to be taking a biguanide
and a statin, and less likely to have a prior revascularization
(Tables 1 and 2).
Medication Compliance and Risk Factor Control
Compliance with the 4 pharmacologic components of inten-
sive medical therapy increased signiﬁcantly from baseline to
Table 4. Cox Proportional Hazards Model for MI
Variables HR 95% CI P Value
P Value for
Interaction
Insulin providing (vs insulin sensitizing)
Current smokers 3.228 1.431–7.281 0.005 0.007
Former/never smokers 0.997 0.772–1.287 0.98
White 0.793 0.610–1.030 0.08
Male sex 0.872 0.671–1.135 0.31
Age (per 5 y) 1.051 0.977–1.131 0.18
Hypercholesterolemia 0.761 0.534–1.084 0.13
Prior revascularization 1.657 1.273–2.156 0.002
HbA1c (per 1 U) 1.102 1.023–1.188 0.011
Baseline biguanide treatment 0.702 0.550–0.895 0.004
Baseline aspirin treatment 0.993 0.670–1.471 0.97
Baseline statin treatment 0.943 0.672–1.324 0.73
Baseline ACEI/ARB treatment 1.508 1.089–2.089 0.014
Baseline beta blocker treatment 1.086 0.816–1.446 0.57
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, conﬁdence interval; HbA1c, glycosylated hemoglobin; HR, hazard ratio; MI, myocardial
infarction.
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5 years in IP and IS groups (Table 2). At 5-year follow-up, 76%
of IS patients and 77% of IP patients were taking aspirin, a
statin, an angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker, and a beta blocker (P=1.00). Control
of individual risk factors for active smokers was similar
throughout the study between IP and IS groups (Table 3).
Overall, risk factor control increased over the 5 years of the
study for smokers in both treatment arms. At year 5, the
mean number of the 5 targeted risk factors controlled
(exclusive of smoking) for IP patients was 3.251.07,
whereas the mean number of risk factors controlled for IS
patients was 2.911.52 (P=0.39).
Outcomes
Fatal or nonfatal MI occurred in 15.4% of smokers randomized
to IP and in 6.8% randomized to IS over the 5-year follow-up
period (P=0.023). Among nonsmokers, fatal or nonfatal MI
occurred in 12% of patients in both IP and IS groups (P=0.84).
Event-free survival curves for smokers and nonsmokers are
presented in Figure 1A and 1B, respectively. Randomization
of smokers to IP therapy was independently associated with a
3.2-fold increase in the hazard of MI compared with
randomization to IS (HR: 3.23; 95% CI, 1.42–7.28; P=0.005;
Table 4), whereas there was no difference in the rate of fatal
Table 5. Biochemical Measures in Active Smokers
Variable IS IP P Value*
Baseline
No. of patients 152 143
PAI-1 activity, AU/mL, median (IQR) 17.5 (10.5–31.0) 19.0 (9.8–29.0) 0.70
PAI-1 antigen, ng/mL, median (IQR) 26.0 (17.0–43.0) 25.5 (17.0–37.0) 0.76
tPA, ng/mL, median (IQR) 10.0 (7.6–13.0) 9.7 (7.2–13.0) 0.48
Insulin, IU/mL, median (IQR) 9.5 (4.8–17.0) 10.0 (6.5–19.0) 0.14
HbA1c, %, mean (SD) 8.091.78 7.531.59 0.006
Year 1
No. of patients 114 103
PAI-1 activity, AU/mL, median (IQR) 16.0 (7.9–27.0) 23.0 (13.0–34.5) 0.001
PAI-1 antigen, ng/mL, median (IQR) 22.5 (18.0–36.0) 33.0 (22.0–48.0) 0.003
tPA, ng/mL, median (IQR) 9.0 (6.9–12.0) 11.0 (8.2–13.0) 0.004
Insulin, IU/mL, median (IQR) 6.8 (4.1–13.0) 10.0 (4.9–17.0) 0.023
HbA1c, %, mean (SD) 7.181.34 7.521.46 0.10
Year 3
No. of patients 112 83
PAI-1 activity, AU/mL, median (IQR) 18.0 (9.6–32.0) 24.0 (13.0–41.0) 0.049
PAI-1 antigen, ng/mL, median (IQR) 24.0 (15.0–37.0) 31.0 (23.0–49.0) 0.008
tPA, ng/mL, median (IQR) 8.8 (5.9–11.0) 11.0 (8.0–13.0) 0.010
Insulin, IU/mL, median (IQR) 7.8 (4.4–11.0) 10.2 (7.0–20.0) 0.038
HbA1c, %, mean (SD) 7.461.75 7.901.52 0.13
Year 5
No. of patients 60 39
PAI-1 activity, AU/mL, median (IQR) 15.0 (9.4–27.0) 29.0 (22.0–35.0) 0.004
PAI-1 antigen, ng/mL, median (IQR) 23.0 (14.0–31.0) 37.0 (26.0–55.0) 0.003
tPA, ng/mL, median (IQR) 9.3 (6.0–11.5) 12.0 (9.6–13.0) 0.009
Insulin, IU/mL, median (IQR) 7.0 (4.1–9.7) 15.0 (8.7–30.0) 0.002
HbA1c, %, mean (SD) 7.782.00 8.061.77 0.59
HbA1c indicates glycosylated hemoglobin; IP indicates insulin provision; IQR, interquartile range; IS, insulin sensitization; PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen
activator.
*Kruskal–Wallis test.
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or nonfatal MI among nonsmokers randomized to IP versus IS
therapy (HR: 1.00; 95% CI, 0.7–1.29; P=0.98). Compared with
nonsmokers, the effect of insulin treatment strategy in active
smokers was signiﬁcantly different with regard to risk of fatal
or nonfatal MI (P=0.007 for interaction). In active smokers,
fatal or nonfatal MI was not inﬂuenced by assignment to the
PCI or CABG strata (P=0.63 for interaction) or by randomiza-
tion to prompt revascularization or intensive medical therapy
(P=0.49 for interaction).
Fibrinolytic Factors
Median baseline PAI-1 activity (17.5 versus 19.0 Au/mL,
P=0.70) and antigen values (26.0 versus 25.5 ng/mL, P=0.76)
were not found to be signiﬁcantly different in active smokers
randomized to IS or IP therapy, respectively (Table 5).
However, active smokers randomized to IP therapy were
found to have signiﬁcantly increased mean PAI-1 activity and
antigen levels at 1 year (23.0 versus 16.0 Au/mL [P=0.001]
and 33.0 versus 22.5 ng/mL [P=0.003]), 3 years (24.0 versus
18.0 Au/mL [P=0.049] and 31.0 versus 24.0 ng/mL
[P=0.008]), and 5 years (29.0 versus 15.0 Au/mL [P=0.004]
and 37.0 versus 23.0 ng/mL [P=0.003]) compared with IS
therapy (Figure 2A and 2B). For nonsmokers (Table 6), mean
baseline PAI-1 activity (15.0 versus 16.0 Au/mL, P=0.85) and
antigen values (23.0 versus 22.0 Au/mL, P=0.91) were also
not found to be signiﬁcantly different in those randomized to IS
or IP therapy (Figure 2A and 2B). At follow-up, however,
nonsmokers randomized to IP therapy were found to have
signiﬁcantly increased PAI-1 activity and antigen levels at 1
year (20.0 versus 13.0 Au/mL [P<0.001] and 27.0 versus
19 ng/mL [P<0.001]), 3 years (19.0 versus 12.0 Au/mL
[P<0.001] and 27.0 versus 19.0 ng/mL [P<0.001]), and
5 years (20.0 versus 15.0 Au/mL [P<0.001] and 27.0 versus
20.0 ng/mL [P<0.001]) compared with IS therapy (Figure 2A
and 2B). PAI-1 activity and antigen levels were signiﬁcantly
greater in active smokers than in nonsmokers at baseline
(19.0 versus 16.0 [P=0.004] and 26.0 versus 23.0 [P<0.001]),
1 year (19.0 versus 16.0 [P=0.03] and 25.0 versus 22.0
[P<0.001]), and 3 years (20.5 versus 15.0 [P<0.001] and 26.0
versus 23.0 [P=0.004]). By year 5, those differences were no
longer found to be signiﬁcant (22.5 versus 17.0 [P=0.06] and
28.0 versus 23.0 [P=0.13]).
In active smokers, tPA levels were not found to be
signiﬁcantly different at baseline for IS or IP therapies (10.0
versus 9.7 ng/mL, P=0.48; Table 5). However, IP-treated
patients had signiﬁcantly increased tPA levels at 1 year (11.0
versus 9.0 ng/mL, P=0.004), 3 years (11.0 versus 8.8 ng/
mL, P=0.01), and 5 years (12.0 versus 9.3 ng/mL, P=0.009)
compared with IS-treated patients. For nonsmokers (Table 6),
no difference was found in tPA levels between IS or IP at
baseline (9.7 versus 9.7 ng/mL, P=0.71). However, IP therapy
was associated with signiﬁcantly increased tPA levels at 1
year (11.0 versus 7.5 ng/mL, P<0.001), 3 years (11.0 versus
7.7 ng/mL, P<0.001), and 5 years (11.0 versus 8.0 ng/mL,
P<0.001) compared with IS therapy.
Insulin levels in active smokers were not found to be
signiﬁcantly different at baseline for IS or IP (9.5 versus
10.0 IU/mL, P=0.14). However, IP therapy was found to have
signiﬁcantly increased insulin levels at 1 year (10.0 versus
6.8 IU/mL, P=0.023), 3 years (10.2 versus 7.8 IU/mL,
P=0.038), and 5 years (15.0 versus 7.0 IU/mL, P=0.002)
compared with IS therapy (Table 5). In smokers, HbA1c levels
were greater at baseline in patients receiving IS therapy;
however, at 1, 3, and 5 years of follow-up, no signiﬁcant
differences were found in HbA1c levels between IS and IP
treatment arms (Table 5). For nonsmokers at baseline, no
difference was found in insulin levels (10.0 versus 9.7 IU/mL,
P=0.80) between IS or IP. However, IP was associated with
signiﬁcantly increased insulin levels at 1 year (9.5 versus
6.3 IU/mL, P<0.001), 3 years (9.7 versus 6.2 IU/mL,
P<0.001), and 5 years (9.5 versus 6.3 IU/mL, P<0.001)
compared with IS (Table 6). At baseline, HbA1c levels were not
A
B
Figure 2. A, Median (ﬁrst, third quartiles) PAI-1 antigen levels in
active smokers and nonsmokers randomized to IP or IS therapy at
baseline and at 12, 36, and 60 mo following randomization. B,
Median (ﬁrst, third quartiles) PAI-1 activity levels in active smokers
and nonsmokers randomized to IP or IS therapy at baseline and at
12, 36, and 60 mo following randomization. IP indicates insulin
provision; IS, insulin sensitization; PAI-1, plasminogen activator
inhibitor 1.
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found to be signiﬁcantly different between IS and IP groups.
However, at 1, 3, and 5 years of follow-up, HbA1c levels were
found to be signiﬁcantly lower in patients treated with IS
(Table 6).
Discussion
The signiﬁcant ﬁndings of this retrospective analysis of a
randomized clinical trial are 3-fold. First, the combination of IP
therapy and active smoking in diabetic patients with SIHD was
associated was a 323% increase in the hazard of fatal or
nonfatal MI over 5.3 years of follow-up. Second, this
association may be mediated through a signiﬁcant increase
in PAI-1 activity in smokers treated with IP therapy compared
with smokers treated with IS therapy. Third, IP therapy also
increased PAI-1 activity in nonsmokers but to a lesser degree
than in active smokers and was not associated with an
increased rate or hazard of MI compared with nonsmokers
treated with IS therapy.
The increased rate of macrovascular complications in
patients with type 2 diabetes mellitus compared with
nondiabetic patients has been attributed to a speciﬁc diabetic
vasculopathy.6 Dysglycemia caused by insulin resistance
initiates structural changes of the vessel wall that culminate
Table 6. Biochemical Measures in Nonsmokers
Variable IS IP P Value*
Baseline
No. of patients 1028 1037
PAI-1 activity, AU/mL, median (IQR) 15.0 (9.7–26.0) 16.0 (9.6–26.0) 0.85
PAI-1 antigen, ng/mL, median (IQR) 22.0 (15.0–34.0) 23.0 (15.0–34.0) 0.91
tPA, ng/mL, median (IQR) 9.7 (7.4–12.0) 9.7 (7.3–12.0) 0.71
Insulin, IU/mL, median (IQR) 10.0 (5.6–17.0) 9.7 (5.8–17.0) 0.80
HbA1c, %, mean (SD) 7.571.58 7.681.61 0.10
Year 1
No. of patients 986 996
PAI-1activity, AU/mL, median (IQR) 13.0 (7.9–23.0) 20.0 (11.0–31.0) <0.001
PAI-1 antigen, ng/mL, median (IQR) 19.0 (13.0–30.0) 27.0 (17.0–40.0) <0.001
tPA, ng/mL, median (IQR) 7.5 (5.4–9.7) 11.0 (8.3–13.0) <0.001
Insulin, IU/mL, median (IQR) 6.3 (3.6–11.0) 9.5 (5.5–18.0) <0.001
HbA1c, %, mean (SD) 6.981.26 7.291.37 <0.001
Year 3
No. of patients 886 911
PAI-1 activity, AU/mL, median (IQR) 12.0 (6.4–23.0) 19.0 (9.6–32.0) <0.001
PAI-1 antigen, ng/mL, median (IQR) 19.0 (13.0–29.0) 27.0 (18.0–40.0) <0.001
tPA, ng/mL, median (IQR) 7.7 (5.5–10.0) 11.0 (8.5–13.0) <0.001
Insulin, IU/mL, median (IQR) 6.2 (3.8–10.0) 9.7 (5.2–18.0) <0.001
HbA1c, %, mean (SD) 6.971.15 7.461.41 <0.001
Year 5
No. of patients 434 463
PAI-1 activity (AU/mL), median (IQR) 15.0 (6.6–27.0) 20.0 (11.0–34.0) <0.001
PAI-1 antigen (ng/mL), median (IQR) 20.0 (12.0–31.0) 27.0 (18.0–42.0) <0.001
tPA (ng/mL), median (IQR) 8.0 (5.9–10.5) 11.0 (8.7–13.0) <0.001
Insulin (IU/mL), median (IQR) 6.3 (4.4–11.0) 9.5 (6.2–19.0) <0.001
HbA1c, mean (SD), % 7.121.22 7.411.31 0.003
HbA1c indicates glycosylated hemoglobin; IP indicates insulin provision; IQR, interquartile range; IS, insulin sensitization; PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen
activator.
*Kruskal–Wallis test.
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in diabetic vascular complications. These alterations in
vascular homeostasis due to endothelial and smooth muscle
dysfunction are the main features of diabetic vasculopathy
that promote a proinﬂammatory/thrombotic state that ulti-
mately leads to atherothrombosis. Insulin resistance pro-
motes atherothrombosis through increased cellular synthesis
of PAI-1 that binds to and inhibits tPA, resulting in impaired
ﬁbrinolysis.6
Aggressive treatment of diabetic patients to speciﬁc
glucose levels as end points of therapy has not resulted in a
reduction in cardiovascular complications14,15; therefore,
targeting the mechanism of hyperglycemia has received
increased attention. Improving insulin sensitivity with drugs
such as metformin, rather than increasing insulin levels with
insulinotropic sulfonylureas, has resulted in improved cardio-
vascular outcomes. In the 10-year follow-up of the UK
Prospective Diabetes Study (UKPDS), metformin-treated
patients had a 33% reduction in MI; this reduction was
signiﬁcantly greater than observed in the sulfonylurea arm,
despite a lack of difference in HbA1c between the metformin
and sulfonylurea arms in the 5 years after the initial study
ended.16 A case–control study found that IS drugs signiﬁcantly
reduced the risk of MI compared with sulfonylurea treat-
ment.17 An analysis of BARI 2D by Chaitman et al found that in
the CABG-stratum patients who had greater atherosclerotic
burden, the reduction of MI seen in patients randomized to
revascularization was found to be signiﬁcant only in those
randomized to an IS treatment strategy.2 Sobel and colleagues
subsequently evaluated the impact of IS and IP treatment
strategies on ﬁbrinolytic biomarker proﬁles in the BARI 2D
trial.7 Although IP therapy was associated with greater PAI-1
antigen and activity, these changes did not translate into any
difference in outcomes in the overall trial. We hypothesized
that the failure to detect a difference in outcomes between
patients randomized to IS or IP in BARI 2D was due to the
intensive treatment of other risk factors such as hypertension
and hyperlipidemia, along with aggressive lifestyle modiﬁca-
tion that mitigated the clinical consequences of prothrombotic
IP therapy on outcomes. We further hypothesized that a
second prothrombotic condition might tip the hemostatic
balance toward a prothrombotic phenotype.
Active smoking is a major risk factor for acute coronary
thrombosis leading to MI.18 Exposure to cigarette smoke
alters the balance of antithrombotic/prothrombotic factors by
affecting the function of endothelial cells, platelets, ﬁbrino-
gen, and coagulation factors along with elevation of PAI-1
activity.18 The dramatic increase in the rate and hazard of
fatal and nonfatal MI in active smokers randomized to IP
therapy in BARI 2D supports a “2-hit” theory for the
development of coronary thrombotic events. That the increase
in MI may be mediated, at least in part, through inhibition of
ﬁbrinolysis is suggested by both the signiﬁcant increase in
PAI-1 activity levels among active smokers in the IP group at
all time points following randomization and the fact that,
although IP therapy also increased PAI activity in nonsmokers,
the magnitude of increase was less in nonsmokers than active
smokers.
Limitations
Our study has several potential limitations. First, there was
crossover between the IS and IP groups. In patients
randomized to IP, 92% of patients were on IP therapy at
5 years, whereas 18% were receiving IS therapy. In patients
randomized to IS, 80% were still taking IS drugs at 5 years,
and 54% were taking IP drugs.8 Second, other mediators of
hypercoagulability such as platelet function were not
measured. Third, although we adjusted for all observed
differences by smoking status, it is not possible to adjust
for unmeasured confounders between active smokers and
nonsmokers. Fourth, smoking status was self-reported with
no biochemical validation of smoking status. Fifth, these
results were achieved in a selected population treated by
speciﬁc protocols in the context of a clinical trial and thus
may not be generalizable to other populations and settings.
Finally, this study was a post hoc subgroup analysis and, as
such, the results can only be considered hypothesis
generating.
Conclusion
In summary, in this post hoc analysis of the BARI 2D trial, we
found that after 5.3 years of follow-up, the combination of
smoking and IP therapy in patients with type 2 diabetes
mellitus and SIHD was associated with a signiﬁcantly
increased hazard of MI. This result may be explained by
higher PAI-1 activity in smokers treated with IP. If conﬁrmed
in future studies, our ﬁndings suggest that diabetic smokers
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